11-dehydro-2,3-dinor-thromboxane b2 profile

**11-dehydro-2,3-dinor-thromboxane B2 (11-dehydro-2,3-dinor-TXB2)** is a metabolite of thromboxane A2 (TXA2), a potent vasoconstrictor and platelet aggregator.

**Structure and Formation:**

* 11-dehydro-2,3-dinor-TXB2 is formed by the enzymatic breakdown of TXA2 through a series of steps.
* It differs from TXB2, the primary metabolite of TXA2, by the removal of two carbon atoms from the carboxyl end of the molecule (dinor) and the presence of a double bond at position 11 (dehydro).

**Importance for Research:**

11-dehydro-2,3-dinor-TXB2 is an important marker for the production of TXA2 in various research settings, including:

* **Cardiovascular Disease:** Elevated levels of 11-dehydro-2,3-dinor-TXB2 in blood or urine have been associated with an increased risk of cardiovascular events, such as heart attack and stroke.
* **Thrombosis:** TXA2 plays a crucial role in platelet aggregation and thrombus formation. Measuring 11-dehydro-2,3-dinor-TXB2 can provide insights into the activity of the TXA2 pathway and its involvement in thrombosis.
* **Inflammation:** TXA2 is also involved in inflammatory processes. 11-dehydro-2,3-dinor-TXB2 can serve as a marker for inflammation in various tissues and conditions.
* **Drug Development:** The measurement of 11-dehydro-2,3-dinor-TXB2 is used to assess the effectiveness of drugs that target the TXA2 pathway, such as antiplatelet agents.

**Advantages over TXB2:**

* 11-dehydro-2,3-dinor-TXB2 has a longer half-life than TXB2, making it a more stable and reliable marker of TXA2 production.
* It is less likely to be affected by other metabolites or factors that can interfere with TXB2 measurements.

**Measurement Methods:**

11-dehydro-2,3-dinor-TXB2 can be measured using various techniques, including:

* Gas chromatography-mass spectrometry (GC-MS)
* Liquid chromatography-mass spectrometry (LC-MS)
* Enzyme-linked immunosorbent assay (ELISA)

**Conclusion:**

11-dehydro-2,3-dinor-TXB2 is a valuable biomarker for research related to cardiovascular disease, thrombosis, inflammation, and drug development. Its stable nature and accurate measurement make it a reliable indicator of TXA2 production in various biological samples.

ID Source	ID
PubMed CID	6443676
MeSH ID	M0218519

Synonym
148682-73-9
3-pentenoic acid, 5-(tetrahydro-4-hydroxy-2-(3-hydroxy-1-octenyl)-2h-pyran-3-yl)-, (2r-(2alpha(1e,3s*),3beta(z),4beta))-
11-dehydro-2,3-dinor-thromboxane b2

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (60.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (20.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	4.09	3	1	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
thromboxanes thromboxane : A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.	2.39	2	0
2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha 2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin F1alpha: formed from 6-keto-PGF1alpha by Mycobacterium rhodochrous; RN given refers to (1R-(1alpha,2beta,3alpha,5alpha))-isomer; structure given in first source	2	1	0
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	3.42	1	1	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	3.82	2	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	3.42	1	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
6-ketoprostaglandin f1 alpha 6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.	3.42	1	1	prostaglandins Falpha	human metabolite; mouse metabolite
11-dehydro-thromboxane b2 11-dehydro-thromboxane B2: structure given in first source. 11-dehydro-thromboxane B2 : A thromboxane obtained by formal oxidation of the hemiacetal hydroxy function of thromboxane B2.	2.39	2	0	thromboxane	human metabolite
2,3-dinor-6-ketoprostaglandin f1alpha 2,3-dinor-6-ketoprostaglandin F1alpha: formed from 6-keto-PGF1alpha by Mycobacterium rhodochrous; RN given refers to (1R-(1alph,2beta(1E,3S*)))-isomer; structure given in first source. 2,3-dinor-6-oxoprostaglandin F1alpha : A prostanoid that is prostaglandin F1alpha lacking two methylenes in the carboxyalkyl chain and bearing an oxo group at the 6-position.	3.42	1	1	4-oxo monocarboxylic acid; prostanoid; secondary alcohol	metabolite
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	9.48	5	1	thromboxanes B	human metabolite; mouse metabolite
2,3-dinor-thromboxane b2 [no description available]	7.39	2	0	thromboxane

Condition	Relationship Strength	Studies
Genetic Predisposition [description not available]	2.03	1
Hypercoagulability [description not available]	2.42	2
Dyslipidemia [description not available]	2.03	1
Coronary Heart Disease [description not available]	2.03	1
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.03	1
Blood Pressure, High [description not available]	2.03	1
Blood Clot [description not available]	2.03	1
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	2.03	1
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	2.03	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.03	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.03	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.03	1
Thrombophilia A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.	2.42	2
Dyslipidemias Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.	2.03	1
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	1.98	1
Anemia, Cooley's [description not available]	2	1
beta-Thalassemia A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.	2	1

11-dehydro-2,3-dinor-thromboxane b2

Cross-References

Synonyms (3)

Research

Studies (5)

Study Types